Randomized Comparison of a Preoperative, Dose-Intensified, Interval-Shortened, Sequential Chemotherapy With Epirubicin, Paclitaxel and CMF [cyclophosphamide + methotrexate + fluorouracil] +/- Darbepoetin Alfa Versus a Preoperative, Sequential Chemotherapy With Epirubicin and Cyclophosphamide Followed by Paclitaxel in Standard Dosage +/- Darbepoetin Alfa in Patients With Primary Breast Cancer.

Trial Profile

Randomized Comparison of a Preoperative, Dose-Intensified, Interval-Shortened, Sequential Chemotherapy With Epirubicin, Paclitaxel and CMF [cyclophosphamide + methotrexate + fluorouracil] +/- Darbepoetin Alfa Versus a Preoperative, Sequential Chemotherapy With Epirubicin and Cyclophosphamide Followed by Paclitaxel in Standard Dosage +/- Darbepoetin Alfa in Patients With Primary Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Darbepoetin alfa (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Methotrexate; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms PREPARE
  • Most Recent Events

    • 29 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Mar 2011 Results published in the Annals of Oncology.
    • 30 May 2008 Interim results reported at ASCO 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top